2-巯基-4,5-二甲氧基-苯甲酸 | 25697-54-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-巯基-4,5-二甲氧基-苯甲酸
• 英文名称: 2-mercapto-4,5-dimethoxy-benzoic acid
• 英文别名: 2-Mercapto-4,5-dimethoxy-benzoesaeure；4,5-dimethoxy-2-mercapto benzoic acid；2-mercapto-4,5-dimethoxybenzoic acid；4,5-dimethoxy-2-mercaptobenzoic acid；4,5-dimethoxy-2-sulfanylbenzoic acid
• CAS: 25697-54-5
• 化学式: C₉H₁₀O₄S
• 分子量: 214.242
• InChiKey: GTHVKCQKTDQFPO-UHFFFAOYSA-N

物化性质

• 熔点：
  184-185 °C(Solv: ethanol (64-17-5))
• 沸点：
  363.4±42.0 °C(Predicted)
• 密度：
  1.317±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  56.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-巯基-4,5-二甲氧基-苯甲酸 在 甲酸 、 双氧水 、 potassium carbonate 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 4,5-Dimethoxy-2-phenylmethanesulfonyl-benzoic acid
  参考文献：
  名称：

  某些2-芳基苯并[b]噻吩-3（2h）-1，1-二氧化物的制备及抗炎活性。

  摘要：

  DOI：

  10.1021/jm00296a009
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 sodium disulfide 作用下， 生成 2-巯基-4,5-二甲氧基-苯甲酸
  参考文献：
  名称：

  Szabo; Vinkler, Acta Chimica Academiae Scientiarum Hungaricae, 1958, vol. 17, p. 201,207

  摘要：

  DOI：

文献信息

• Pharmaceutical compounds
  申请人：Lilly Industries Limited

  公开号：US05338735A1

  公开（公告）日：1994-08-16

  Compounds of the formula: ##STR1## in which each R.sup.1 is hydrogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, halogen or nitro, and n is 0, 1, 2 or 3, R.sup.2 is hydrogen, C.sub.1-4 alkyl or C.sub.2-4 alkenyl, R.sup.3 and R.sup.4 are each hydrogen, C.sub.1-4 alkyl, optionally substituted phenyl or C.sub.6-9 cycloalkyl optionally substituted by 1 to 4 C.sub.1-4 alkyl groups, R.sup.5 is optionally substituted phenyl, tetrahydronaphthyl, phthalimido, saccharinyl, glutaramido, C.sub.6-10 cycloalkyl optionally substituted with 1 to 4 C.sub.1-4 alkyl groups or a phenyl group, or C.sub.4-9 heterosubstituted cycloalkyl optionally substituted with 1 to 4 alkyl groups, x is 1, 2 or 3, y is 0 or 1 and z is 0, 1, 2 or 3; and salts thereof. The compounds are indicated for use in the treatment of disorders of the central nervous system.

  式为：##STR1##，其中每个R.sup.1是氢、C.sub.1-4烷基、C.sub.1-4烷氧基、卤素或硝基，n为0、1、2或3，R.sup.2是氢、C.sub.1-4烷基或C.sub.2-4烯基，R.sup.3和R.sup.4分别是氢、C.sub.1-4烷基、可选择取代的苯基或C.sub.6-9环烷基，可选择取代1至4个C.sub.1-4烷基，R.sup.5是可选择取代的苯基、四氢萘基、邻苯二甲酰亚胺基、糖精基、戊二酰亚胺基、C.sub.6-10环烷基，可选择取代1至4个C.sub.1-4烷基或苯基，或C.sub.4-9杂原子取代的环烷基，可选择取代1至4个烷基，x为1、2或3，y为0或1，z为0、1、2或3；及其盐。这些化合物适用于治疗中枢神经系统疾病。
• 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1424336A1

  公开（公告）日：2004-06-02

  This invention provides a compound represented by the formula (I) : wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I) , which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.

  这项发明提供了一种由以下式（I）表示的化合物： 其中R1是氢原子、卤素原子、羟基、硝基、可选择具有卤素取代基的烷基、可选择具有取代基的烷氧基、酰基或氨基； R2是吡啶基、呋喃基、噻吩基、吡咯基、喹啉基、吡嗪基、嘧啶基、吡啶并嘧啶基、吲哚基、四氢喹啉基或噻唑基，每种基团可能具有取代基； n为1或2；或其盐。该发明提供了一种安全的药物，包括具有优异的凋亡抑制作用和MIF结合作用的式（I）化合物，用于预防和/或治疗心脏病、神经退行性疾病、脑血管疾病、中枢神经感染性疾病、创伤病变、脱髓鞘疾病、骨骼和关节疾病、肾脏疾病、肝脏疾病、骨髓发育不良、艾滋病、癌症等。
• Spirocyclopropane compounds. VI Synthesis of spiro(benzo(b)thiophene-2(3H),1'-cyclopropan)-3-ones.
  作者：MITSURU KAWADA、HIROSADA SUHIHARA、ISUKE IMADA

  DOI：10.1248/cpb.34.1939

  日期：——

  Spiro[benzo[b]thiophene-2(3H), 1'-cyclopropan]-3-ones (IIIc-1-IIIc-11) and their aza analogs, such as spiro[cyclopropane-1, 2'(3'H)-thieno[3, 2-c]pyridin]-3'-one (IIIc-12) as well as spiro[cyclopropane-1, 2'(3'H)-thieno[2, 3-b]pyridin]-3'-one (IIIc-13), were synthesized from thiosalicylic acids and from 4- and 2-mercaptonicotinic acids, respectiely, in three steps. Decarboxylation of 4', 5'-dihydrospiro[benzo[b]thiophene-2(3H), 3'(2'H)-furan]-2', 3-diones (IIc) gave 2, 3-dihydrobenzo[b]thieno[3, 2-b]furans (IVc) along with the desired spirocyclopropane compounds (IIIc).The ratios of IIIc to IVc were greatly influenced by the substituents on the benzene ring.

  Spiro[苯并[b]噻吩-2(3H), 1'-环丙烷]-3-酮 (IIIc-1-IIIc-11) 及其氮杂类，如spiro[环丙烷-1, 2'(3'H)-噻吩[3, 2-c]吡啶]-3'-酮 (IIIc-12) 和spiro[环丙烷-1, 2'(3'H)-噻吩[2, 3-b]吡啶]-3'-酮 (IIIc-13)，分别由硫水杨酸和4-、2-巯基烟酸经过三步反应合成。4', 5'-二氢spiro[苯并[b]噻吩-2(3H), 3'(2'H)-呋喃]-2', 3'-二酮 (IIc) 的脱羧反应产生了2, 3-二氢苯并[b]噻吩[3, 2-b]呋喃 (IVc) 以及所需的spiro环丙烷化合物 (IIIc)。IIIc与IVc的比例受到苯环上取代基的显著影响。
• Iron-Ligand Coordination in Tandem Radical Cyclizations: Synthesis of Benzo[b]thiophenes by a One-pot Reaction of Iron 1,3-Diketone Complexes with 2-Thiosalicylic Acids
  作者：Sharon Lai-Fung Chan、Kam-Hung Low、Chen Yang、Samantha Hui-Fung Cheung、Chi-Ming Che

  DOI：10.1002/chem.201100377

  日期：2011.4.18

  Iron—the mediator: 1,3‐Diketone ligands coordinated to iron undergo unprecedented tandem reactions with 2‐thiosalicylic acids to give 2‐substituted 3‐hydroxylbenzo[b]thiophenes in up to 98 % yield. A similar reaction with 2‐mercaptonicotinic acid gave a thieno[2,3‐b]pyridine derivative in 72 % yield (see scheme). A mechanism involving redox transformation and tandem radical cyclization of the coordinated

  铁—介体：与铁配位的1,3-二酮配体与2-硫代水杨酸进行空前的串联反应，生成2-取代的3-羟基苯并[ b ]噻吩，收率高达98％。与2-巯基烟碱酸的类似反应得到噻吩并[2,3- b ]吡啶衍生物，产率为72％（参见方案）。提出了涉及配体的氧化还原转化和串联自由基环化的机理。
• 1, 3-benzothiazinone derivatives and use thereof
  申请人：Kajino Masahiro

  公开号：US20050032786A1

  公开（公告）日：2005-02-10

  This invention provides a compound represented by the formula (I): wherein R 1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; R 2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I), which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.

  该发明提供了一个由式(I)表示的化合物：其中R1是氢原子、卤素原子、羟基、硝基、可选取代卤代烷基、可选取代基的烷氧基、酰基或氨基；R2是吡啶基、呋喃基、噻吩基、吡咯基、喹啉基、吡嗪基、嘧啶基、吡嗪啉基、吲哚基、四氢喹啉基或噻唑基，每个基团都可以有取代基；n为1或2；或其盐。该发明提供了一种安全的药物，包括式(I)化合物，具有出色的抑制细胞凋亡和结合MIF的效果，用于预防和/或治疗心脏病、神经退行性疾病、脑血管疾病、中枢神经感染性疾病、创伤性疾病、脱髓鞘疾病、骨骼和关节疾病、肾脏疾病、肝脏疾病、骨髓发育不良、艾滋病、癌症等疾病。